Drug Trial Radar · NCT05153135
Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors
Last checked: Nov 19, 2026Latest source record: Dec 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,320
Actual
Start
May 8, 2020
Primary completion
Jul 31, 2020
Study completion Jul 31, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 10, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study was an observational, retrospective cohort design, using US administrative insurance claims data, to better understand Healthcare resource utilization (HRU) and healthcare costs among women with mBC initiated on a CDK4/6 inhibitor.
Conditions
- Metastatic Breast Cancer
Interventions
RibociclibDrug
Participants who initiated CDK4/6i therapy
PalbociclibDrug
Participants who initiated CDK4/6i therapy
AbemaciclibDrug
Participants who initiated CDK4/6i therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of inpatient (IP) admissionsTime frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)
- Number of IP daysTime frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)
- Number of days with durable medical equipment (DME) servicesTime frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)
- Number of days with emergency department (ED) visitsTime frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)
- Number of days with outpatient (OP) services or visitsTime frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)
- Other medical servicesTime frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)
- Total healthcare costs (medical service + pharmacy costs)Time frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
East Hanover, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.